Cathelicidin Is Essential for Protecting Your Colon Against Bacterial Infection
Mice without the cathelicidin antimicrobial peptide gene developed dramatically worse intestinal infections, proving cathelicidin is a critical first-line defense in the colon.
Quick Facts
What This Study Found
Mice lacking the cathelicidin gene (Cnlp-/-) were dramatically more vulnerable to intestinal infection than normal mice. When infected with Citrobacter rodentium — a pathogen that mimics dangerous human E. coli strains — cathelicidin-deficient mice developed significantly greater colon colonization, epithelial cell damage, and systemic spread of infection. Normal mice were protected from infection doses that reliably infected the knockout mice.
The study also showed that cathelicidin (mCRAMP) expression in the gut is concentrated in the colon's surface epithelial cells, and that colon cell extracts from normal mice killed C. rodentium significantly better than extracts from cathelicidin-deficient mice.
Key Numbers
Cnlp+/+ vs Cnlp-/- knockout mice · Citrobacter rodentium infection model · Significantly greater colonization in knockouts · Epithelial cell damage increased · Systemic dissemination in knockouts · mCRAMP concentrated in colon surface epithelium
How They Did This
Knockout mouse study comparing cathelicidin-deficient (Cnlp-/-) mice to normal (Cnlp+/+) mice. Researchers mapped mCRAMP expression in the intestinal tract, tested synthetic mCRAMP's antimicrobial activity against C. rodentium in vitro, compared antimicrobial activity of colon cell extracts from both mouse types, and challenged both groups with oral C. rodentium infection to measure colonization, tissue damage, and systemic spread.
Why This Research Matters
This study provided some of the first direct evidence that cathelicidin — the same antimicrobial peptide family that includes human LL-37 — is a critical defender of your colon against bacterial infection. It established that without cathelicidin, the colon is essentially unprotected against adherent bacterial pathogens, the same class of bacteria responsible for serious human infections like enteropathogenic and enterohemorrhagic E. coli.
The Bigger Picture
This 2005 study was foundational in establishing that antimicrobial peptides aren't just backup defenses — they're essential. The finding that cathelicidin-deficient mice can't control colon infections helped shift the field's understanding of innate immunity in the gut. It also laid groundwork for research into whether reduced LL-37 expression might contribute to inflammatory bowel disease and other gut conditions in humans.
What This Study Doesn't Tell Us
Mouse study using a murine pathogen (C. rodentium) as a model for human E. coli infections — direct translation to humans requires caution. The study focused on one pathogen type. mCRAMP is the mouse equivalent of human LL-37 but the two peptides have structural differences. The relative contribution of cathelicidin versus other antimicrobial defenses was not fully quantified.
Questions This Raises
- ?Do people with low LL-37 levels have increased susceptibility to intestinal infections from pathogenic E. coli?
- ?Could supplemental cathelicidin or LL-37 help protect against gut infections in immunocompromised patients?
- ?How does cathelicidin interact with other antimicrobial peptides like defensins in the colon's defense system?
Trust & Context
- Key Stat:
- Cathelicidin-deficient mice couldn't resist infections normal mice fought off Oral infection doses that were handled by normal mice caused extensive colon damage and systemic bacterial spread in mice lacking cathelicidin — demonstrating this peptide is not optional for gut defense.
- Evidence Grade:
- Rated moderate: well-designed knockout mouse study with clear controls and consistent results across multiple outcome measures. The use of genetic knockouts provides strong mechanistic evidence, though findings are in mice, not humans.
- Study Age:
- Published in 2005. This is a foundational study that established cathelicidin's role in intestinal defense. Its findings have been widely cited and confirmed by subsequent research on antimicrobial peptides in gut immunity.
- Original Title:
- Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens.
- Published In:
- Journal of immunology (Baltimore, Md. : 1950), 174(8), 4901-7 (2005)
- Authors:
- Iimura, Mitsutoshi, Gallo, Richard L(10), Hase, Koji, Miyamoto, Yukiko, Eckmann, Lars, Kagnoff, Martin F
- Database ID:
- RPEP-01049
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is cathelicidin and why does your colon need it?
Cathelicidin is an antimicrobial peptide — a natural antibiotic your body produces. In the colon, it's made by the surface lining cells and acts as a first line of defense against dangerous bacteria that try to attach to and invade the gut wall. Without it, bacteria can colonize, damage tissue, and spread through the body.
Is this the same as LL-37?
Yes — LL-37 is the human version of cathelicidin, and mCRAMP is the mouse version studied here. While they have some structural differences, they serve the same essential function: killing bacteria and protecting mucosal surfaces like the gut lining.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01049APA
Iimura, Mitsutoshi; Gallo, Richard L; Hase, Koji; Miyamoto, Yukiko; Eckmann, Lars; Kagnoff, Martin F. (2005). Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens.. Journal of immunology (Baltimore, Md. : 1950), 174(8), 4901-7.
MLA
Iimura, Mitsutoshi, et al. "Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens.." Journal of immunology (Baltimore, 2005.
RethinkPeptides
RethinkPeptides Research Database. "Cathelicidin mediates innate intestinal defense against colo..." RPEP-01049. Retrieved from https://rethinkpeptides.com/research/iimura-2005-cathelicidin-mediates-innate-intestinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.